Last reviewed · How we verify
Breakthrough Therapy Designation explained
What Breakthrough Therapy actually means
Breakthrough Therapy (BTD) is a designation introduced by the Food and Drug Administration Safety and Innovation Act (FDASIA) in 2012. It applies to drugs treating serious conditions where preliminary clinical evidence shows substantial improvement over existing therapies on a clinically significant endpoint. Sponsors apply with Phase 1 or early Phase 2 data; the FDA decides within 60 days.
Benefits of the designation
BTD unlocks: (1) Intensive FDA guidance during clinical development, with senior reviewers attending sponsor meetings; (2) Eligibility for rolling NDA/BLA review — submit modules as they're ready instead of one big package; (3) Eligibility for priority review (6 months instead of 10); (4) Marketing + scientific implications — investors interpret BTD as positive validation, often moving the stock 10-20% on announcement.
What "substantial improvement" means
The FDA looks for clinically meaningful improvement on a primary outcome (response rate, survival, hospitalisation reduction) compared to standard of care. The improvement must be substantial — not just statistically significant. For oncology, a doubling of response rate or 50%+ survival extension qualifies. For non-oncology, the bar is similarly material.
How often is BTD granted
Since the programme launched in 2012, the FDA has granted >450 BTDs. The grant rate is ~30% of requests. Oncology accounts for ~45% of grants; rare disease ~25%; infectious disease ~10%. Recent BTDs include: lecanemab (Leqembi, Alzheimer's), donanemab (Kisunla, Alzheimer's), ritlecitinib (Litfulo, alopecia), trastuzumab deruxtecan (Enhertu, multiple HER2 cancers).
BTD vs other designations
BTD is one of several expedited pathways. Fast Track is broader (no clinical data required) but offers fewer benefits. Accelerated Approval permits surrogate-endpoint approval (e.g. tumour response instead of survival). Priority Review shortens the FDA review clock. Orphan Drug provides exclusivity + tax credits for rare disease. A single drug can hold multiple designations simultaneously.
FAQ
Does Breakthrough Therapy guarantee FDA approval?
No. BTD is a development-stage acceleration tool. The drug still needs to demonstrate safety + efficacy in Phase 3. About 65% of BTD-designated drugs ultimately reach approval — higher than the 12-14% Phase-1-to-approval rate but not certain.
Can sponsors apply for BTD at any time?
Any time after Phase 1, though earlier is better. The FDA recommends applying when sponsors first have data supporting substantial improvement — typically end-of-Phase-1 or interim Phase 2. Late applications (Phase 3 or pre-NDA) are accepted but offer less benefit.
How is BTD different from "Fast Track" designation?
Fast Track requires only preclinical evidence of activity for a serious condition; BTD requires clinical data showing substantial improvement. Fast Track is broader + earlier; BTD is more selective + later. Drugs can hold both.
Does BTD speed up FDA review?
Indirectly. BTD itself doesn't shorten the review clock, but it grants eligibility for Priority Review (6-month clock) and rolling submission (allowing modular review). Combined, BTD typically saves 3-6 months over standard review.